Please assess the completion status of the following clinical trial:

Trial Title: A Study of Avonex to Determine the Effects of Dose Titration on the Incidence of Flu Like Symptoms in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a Body Mass Index of 19 to 30 kg/m2, and a minimum body weight of 50.0 kg at Screening.~* Female participants of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.~Key Exclusion Criteria:~* Known history of or positive test result for human immunodeficiency virus (HIV), hepatitis C virus (test for hepatitis C virus antibody \[HCV Ab\]) or hepatitis B virus (test for hepatitis B surface antigen \[HBsAg\] and hepatitis B core antibody \[HBcAb\])~* Known history of chronic fatigue syndrome or fibromyalgia~* Within one month, flu-like illnesses (e.g., gastroenteritis, upper respiratory infection, common cold)~* History of severe allergic reactions to any drug or anaphylactic reactions~* Known allergy to Avonex or any of its components~* Serious infection (e.g., pneumonia, septicemia) within the 3 months prior to Screening or active bacterial or viral infection~* History of alcohol or substance abuse (as defined by the Investigator)~* Female participants who are pregnant or currently breastfeeding~* Any previous treatment with any interferon product.10. Vaccinations within 2 weeks or 5 half-lives, whichever is longer, prior to Day 1~* Blood donation within 30 days prior to Screening~* Use of any tobacco product more than 5 times within 30 days prior to Screening~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): No dose titration
- Group 2 (Type: EXPERIMENTAL): Fast dose titration
- Group 3 (Type: EXPERIMENTAL): Slow dose titration

Based on this trial design, predict the completion outcome and termination type (if applicable).